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Abstract
There are numerous causes of acute hepatic failure (AHF). Cerebral edema, coagulopathy, renal failure, metabolic
disturbances and infection are the main clinical sequelae. Patients with AHF should be stabilized when first encountered
and transferred to the nearest liver transplant center, as AHF progresses quickly and is often fatal. There are few adequate
medical interventions and care of patients with AHF is supportive until spontaneous recovery ensues. If recovery does not
appear to occur, most causes of AHF are well accepted indications for liver transplantation.
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Introduction
Acute hepatic failure (AHF) has many causes
(Table I). It has classically been known as fulminant
hepatic failure and was defined in 1970 as occurring
in patients with no prior liver disease in which rapid
onset of hepatocellular dysfunction ensues with asso-
ciated encephalopathy within 8 weeks of initial pre-
sentation [1]. In 1993, O’Grady et al. [2] redefined
the term AHF as the clinical syndrome where
encephalopathy occurs between 8 and 28 days after
the onset of jaundice. Patients with AHF should be
evaluated and stabilized when first encountered.
Transfer to the nearest center with liver transplant
capabilities should then occur rapidly, as AHF pro-
gresses quickly and is often fatal. There are few
adequate medical interventions and care of patients
with AHF is supportive until spontaneous recovery
ensues. If recovery does not appear to occur, most
causes of AHF are well accepted indications for liver
transplantation [3].
Etiology of AHF
Drug-induced AHF
Drug-induced AHF is the most common cause of
AHF in the United States, and accounts for 15% of all
transplants. It is also the most common cause of AHF
in the UK. Acetaminophen (APAP) overdose,
whether intentional or accidental, is the most com-
mon agent causing AHF.
Russo et al. [4] examined the United Network for
Organ Sharing (UNOS) liver transplant database
from 1990 to 2002 and found that APAP overdose
accounted for 46% of patients who underwent liver
transplant for drug-induced AHF. APAP combined
with another drug accounted for 3% of transplants
and nonAPAP drugs alone or in combination ac-
counted for the remaining 51% of liver transplants for
AHF.
After APAP, the next most common drugs in
descending order of frequency are as follows: isonia-
zid, propylthiouracil, phenytoin, and valproate [3].
Other less frequent causes of AHF are toxic mush-
rooms containing amatoxins [5], disulfiram [6],
herbal remedies [7], iron toxicity [8], and various
other drugs.
Virus-induced AHF
Acute viral hepatitis causing AHF is most commonly
caused by hepatitis A or hepatitis B viruses. Hepatitis
A and B are still the most common cause of AHF in
Japan and France and the second leading cause of
AHF in India behind hepatitis E [9]. Schiødt et al.
[10] demonstrated that viral hepatitis in the United
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States is no longer the major cause of AHF. In
addition, they demonstrated that hepatitis A patients
had a significantly higher spontaneous recovery and a
lower liver transplantation rate when compared with
AHF due to hepatitis B. Hepatitis C causing ALF is
rare in the United States and Europe, but numerous
reports have come from Japan [11]. Other less
common causes of virus-induced AHF are hepatitis
E [12] (except in India), cytomegalovirus [13], herpes
simplex virus [14], and Epstein/Barr virus [15].
Other causes
Other less common causes of AHF are acute fatty liver
of pregnancy [16], lymphoma [17], ischemic hepatitis
[18], acute Budd-Chiari syndrome [19], and acute
Wilson disease [20]. In addition, autoimmune disease
[21] and peripartum cardiomyopathy [22] have been
described as causes of AHF.
Manifestations of acute hepatic failure
Encephalopathy and cerebral edema
The most lethal complication associated with acute
liver failure is the development of encephalopathy and
cerebral edema, which can lead to uncal herniation
and death. In patients with chronic hepatic failure, the
standard of care is lactulose therapy and bacterial
decontamination of the gastrointestinal tract with
neomycin. These therapies are not effective in AHF
[23]. The encephalopathy of AHF is progressive and
life-threatening. It begins with euphoria, anxiety,
asterixis or flapping tremor, and can progress to
lethargy, somnolence, coma, and death. Electroence-
phalogram findings are also progressive in nature and
range from suppressed alpha rhythms and more
prevalent beta rhythms to diffuse bilateral hemi-
spheric asynchronous delta and theta waves with
severely disorganized activity [24]. Patients with
AHF should have their encephalopathy graded using
the West Haven grading system [25] as shown in
Table II. In patients whose encephalopathy does not
progress past grades 1 or 2, prognosis is excellent. The
prognosis for spontaneous liver recovery in patients
with grades 3 and 4 is 40% and 20%, respectively
[26]. In addition, hepatic encephalopathy of grades 3
or 4 should undergo transfer to an intensive care
setting and endotracheal intubation for airway protec-
tion. As cerebral edema evolves, treatment should
focus on the preservation of cerebral perfusion to
prevent ischemia. The intracerebral pressure (ICP)
should be measured directly [27]. Cerebral perfusion
pressure (CPP) defined as systemic blood pressure
minus ICP must be maintained above 40 mm Hg.
The mainstay of therapy for treatment of elevated ICP
comprises sedation, hypertonic saline, and mannitol
[28]. Finally, hypothermia is a modality that has
recently been explored that has been shown to lower
ICP in those with intracranial hypertension and to
prevent the development of intracranial hypertension
in those with encephalopathy who have yet to develop
it [29].
Coagulopathy
An important manifestation of AHF is coagulopathy.
This is typically measured using prothrombin time
(PT) or international normalized ratio (INR). Coa-
gulopathy occurs due to decreased synthesis of clot-
ting factors, an increase in peripheral consumption,
and at least some degree of disseminated intravascular
coagulation and thrombocytopenia [30]. Severe coa-
gulopathy can lead to spontaneous hemorrhage,
especially from the gastrointestinal tract. Prophylactic
treatment with fresh frozen plasma (FFP) in the
Table II. West Haven criteria for grading mental state in hepatic encephalopathy.
Grade Features
Grade 0 No signs or symptoms
Grade 1 Euphoria, anxiety, trivial lack of awareness, impaired performance, shortened attention span, mild asterixis
Grade 2 Lethargy, minimal personality changes, subtle personality change, inappropriate behavior, asterixis
Grade 3 Somnolence, confusion, gross disorientation
Grade 4 Coma
Table I. Causes of acute hepatic failure.
Drug-induced Viral causes Other causes
Acetaminophen (APAP) Hepatitis A, B, C, E Acute fatty liver of pregnancy
Isoniazid Cytomegalovirus Lymphoma
Propylthiouracil Epstein/Barr virus Ischemic hepatitis
Phenytoin Herpes simplex virus Acute Budd-Chiari syndrome
Valproate Acute Wilson disease
Autoimmune disease
Peripartum cardiomyopathy
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absence of bleeding is unadvised for two reasons.
First, the administration of FFP will lower the PTand
will thus decrease the accuracy with which prognosis
can be judged. In addition, this can present as a
significant volume challenge, thus exacerbating those
who may be in renal failure and contributing to
increases in ICP [31]. Patients with AHF should be
placed on H2 receptor antagonists and/or proton
pump inhibitors to reduce the risk of spontaneous
hemorrhage from the upper gastrointestinal tract.
Plasmapheresis can also play a role in patients with
AHF and life-threatening bleeds. Although plasma-
pheresis will not help the liver regenerate or impact
the neurologic complications of AHF, it can help to
maintain a more normal coagulation profile and
lessen the chance of life-threatening hemorrhage [32].
Renal failure
Renal failure is another manifestation of AHF that is
multifactorial in nature. Some drugs when taken in
excess, such as APAP, cause injury to nephrons and
result in renal failure in addition to AHF. Volume
depletion and systemic hypoperfusion can cause acute
tubular necrosis and renal failure or exacerbate
existing renal failure. The hepatorenal syndrome is
another cause of acute renal failure. It is characterized
by intense constriction of renal cortical vasculature
with resulting oliguria and sodium retention. It is
defined as functional renal failure in the setting
of cirrhosis in histologically normal kidneys [33].
Finally, sepsis and a decrease in peripheral vascular
resistance can also either cause or exacerbate renal
failure. Many patients will go on to require hemodia-
lysis as a result of renal failure. Continuous hemodia-
lysis is preferred to intermittent, so as to avoid large
variations in volume status and increases in CPP.
Infection
Patients with AHF are functionally immunosup-
pressed and bacterial or fungal infection is common
and can be detrimental. In addition, most patients
with AHF will require central venous access and
mechanical ventilation, which also increase the risk
of infection. Infections have been temporally asso-
ciated with a worsening encephalopathy, especially in
APAP overdose [34]. Approximately 60% of patients
with AHF will become infected and many of these will
develop a systemic inflammatory response syndrome
(SIRS). The mortality rate for patients who go on to
develop severe sepsis or septic shock is 59% and 98%,
respectively [35]. The utility of prophylactic antibio-
tics in AHF has not been established. Furthermore,
detecting an infection can be quite difficult due to
manifestations of numerous metabolic disturbances
induced by AHF. Serial blood cultures for bacteria
and fungi are appropriate for detecting infections. A
high index of suspicion must be maintained and
antibiotics should be administered with a low thresh-
old when it is felt to be appropriate.
Metabolic disturbances
Numerous metabolic disturbances accumulate during
AHF. Hypoglycemia occurs due to increasing levels of
insulin, an inability to mobilize glycogen stores, and
impaired gluconeogenesis. Hypoglycemia responds to
intravenous administration of glucose. Metabolic
acidosis can occur. This is multifactorial and depends
on the mechanism of hepatic injury. Typically, it is a
metabolic acidosis and results from the direct effects
of hepatotoxic drugs such as APAP. In addition, this
can be the manifestation of global hypoperfusion and
lactic acidosis due to volume depletion [36]. Several
other manifestations such as hypophosphatemia,
hyponatremia, and alkalosis can occur.
Cardiovascular
The cardiovascular manifestations of AHF are similar
to systemic sepsis. They are characterized by vasodi-
latation with a compensatory increase in cardiac
output. These effects are thought to be mediated by
circulating endotoxin and tumor necrosis factor.
Hypovolemia compounds the effects of AHF. Pul-
monary artery catheters are warranted to assess the
adequacy of filling pressures as well as other hemo-
dynamic parameters. If hypotension ensues, prognosis
worsens. Hypotension leads to lower CPP and dee-
pening encephalopathy with rising ICP. Treatment
goals are to restore the circulating volume and
supportive care with vasopressors.
Arrhythmias are another manifestation of AHF.
Arrhythmias typically result from a definable source
such as electrolyte imbalance. Therapy is directed at
the underlying cause of the arrhythmia.
Prognostic factors
Initial efforts in the treatment of AHF are aimed at
delineating the underlying cause. Ostapowicz et al.
[37] studied 308 patients prospectively over a 41-
month period and determined that patients with AHF
from APAP overdose, hepatitis A, ischemic hepatitis,
or pregnancy-related acute liver failure had a short-
term survival (3 weeks) without transplantation of
]/50%. Patients whose AHF was from indeterminate
causes, nonAPAP drug overdose, hepatitis B virus,
autoimmune hepatitis, Wilson disease, or Budd-
Chiari syndrome had lower rates of short-term
transplant-free survival (B/25%).
Symptom duration has also been used to assess
prognosis. Patients with nonAPAP-related liver failure
can be stratified into three subsets: hyperacute, acute,
and subacute liver failure [2]. Hyperacute liver failure
is the onset of hepatic encephalopathy within 7 days of
symptoms. Acute failure is 8/28 days of symptoms
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before onset of encephalopathy. Finally, subacute
failure is the onset of hepatic encephalopathy after
28 days of symptoms. Short-term, transplant-free
survival is worse in patients with the subacute group
of AHF (14%) than patients in the hyperacute (30%)
or acute (33%) groups [30].
Several other variables have been used to identify
their effect on survival. Body mass index, age, serum
bilirubin, and serum creatinine seem to be the most
important [38,39]. Children with AHF rarely develop
hepatic encephalopathy and if it occurs, it is an
ominous sign. Therefore, different factors play a
role. The main prognostic factor is PT or INR. A
PT prolonged beyond 90 s or an INR /4 are
associated with a mortality that exceeds 90% [40].
Liver support systems
There have been attempts at artifical liver replace-
ment in the setting of AHF. In general, there are two
types of artifical liver replacement, cell-based thera-
pies and dialysis-based therapies or plasmapheresis.
Liver support systems that do not use biologic
tissue include extracorporeal albumin dialysis
(ECAD), molecular absorbent recycling systems
(MARS), and plasmapheresis. Although there has
been anecdotal support for these techniques, data in
support of these techniques in AHF are scant [41].
Two liver support systems that do use biologic
means to support patients in AHF have also been
evaluated in the past 10 years. One incorporated
porcine hepatocytes, the other a hepatoblastoma cell
line. Unfortunately, these have also failed to show a
proven benefit against supportive care alone [9].
To date, 11 different devices have been reported in
clinical application and 3 of these have been studied in
randomized controlled clinical trials, none of which
have shown a survival benefit [42]. In general, artifical
support systems have failed to show significant
survival benefit in controlled trials and have been
used as a ‘bridge’ to transplantation in patients with
AHF. Sekido et al. [43] have reported improvements
in pulmonary and circulatory profiles among pre-
transplant patients before receiving a live donor
hepatic graft.
Selection criteria for transplantation
UNOS has developed a special status 1 category for
patients with AHF. The definition of status 1 for
adults includes those with AHF and encephalopathy
who are in an intensive care unit with a life expectancy
of B/7 days without a liver transplant. In children
under 18 years of age, status 1 includes those in an
intensive care unit with acute or chronic liver disease
who have experienced one of the following: gastro-
intestinal bleeding, hepatorenal syndrome, refractory
ascites, uncontrolled portosystemic encephalopathy,
and an estimated life expectancy of B/7 days. Status 1
also includes patients with primary graft failure,
hepatic artery thrombosis B/7 days post transplant,
or fulminant Wilson disease.
There are several factors that are important in the
prognosis of patients with AHF. Several predictive
models have been developed to determine when
liver transplantation is indicated. The most widely
accepted criteria are the King’s College criteria
(Table III). The model for end-stage liver disease
(MELD) and the pediatric end-stage liver disease
(PELD) systems are detailed in Table IV. While the
MELD/PELD was developed to predict mortality in
patients with chronic liver disease, it has recently been
compared to the King’s College criteria. The MELD/
PELD appears to be an excellent predictor of out-
come in both adults and children with AHF. In
addition, there appear to be a lower false negative
rate with MELD/PELD, which would predict fewer
transplants for patients who would have sponta-
neously recovered [44].
Results of transplantation for AHF
Approximately 5% of patients who are on the UNOS
waiting list have AHF and are listed as status 1. From
1994 to 2003, 49% of these patients received liver
transplantation within 15 days of being listed [45].
Patients with AHF who received transplant had a
1-year survival rate of 81% during this same time
period. In addition, this same group of patients
had a graft survival of 83% at 3 months and 75%
at 1 year post transplant. Furthermore, 18% of status
1 patients died during this same time period awaiting
Table III. King’s College criteria for liver transplantation in AHF.
APAP-associated AHF All other causes of AHF
pHB/7.3 INR /6.5
or or
INR/6.5, serum creatinine /3.4 mg/dl, and grade III/IV Three of the following variables:
encephalopathy 1. Age B/10 or /40 years
2. Cause is nonA, nonB hepatitis or idiosyncratic drug reaction
3. Duration of jaundice before encephalopathy /7 days
4. INR/3.5
5. Serum bilirubin /17.5 mg/dl
APAP, acetaminophen; INR, international normalized ratio.
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transplantation. Meanwhile, 88% of patients under-
going transplantation for reasons other than AHF
survived for 1 year. These results are similar to those
found in Europe. According to the European Liver
Transplant Registry (ELTR), in a 13-year period
ending in 2001, the ELTR had a 1-year graft survival
of 60% and a 1-year patient survival of 65% for all
forms of AHF [46]. Other small studies have also
determined that there is a worse post transplant
patient survival after liver transplantation on an
urgent basis [47]. In addition, it should be noted
that as the stage of encephalopathy progresses (I to
IV), patient survival subsequently worsens [2].
These results have led to the sharing of organs for
status 1 patients within specific regions in the United
States. Sharing of organs within regions has led to
shorter waiting times and improved post transplant
survival, with a subsequent decrease in waiting list
mortality and postoperative complications [48].
Due to the shortage of suitable organs for trans-
plantation and the high mortality associated with
AHF, some have suggested living donation for
patients with AHF. In Asia, living donors for patients
with AHF have been used as a proactive way to
increase the organ pool with success and this has been
shown to be a viable option [49,50].
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